Literature DB >> 6825436

Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes.

F W Jennings, G D Gray.   

Abstract

Mice infected with Trypanosoma brucei can be easily cured using the available trypanocidal drugs, provided treatment is given soon after the infection; however, if infection is allowed to continue for some time then it is extremely difficult to obtain a permanent cure, and after an aparasitaemic period the infection eventually relapses. It has been shown that a relatively small number of infective trypanosomes in the brain have escaped the action of the drug and these are able to replicate and eventually they re-establish a circulating parasitaemia. The number of infective trypanosomes remaining after chemotherapy varied according to the stabilate of T. brucei, but using the stabilate T. brucei GVR 35 there were up to, 5,000 infective trypanosomes 2 days after treatment, and this rapidly increased up to 50,000 trypanosomes at 7 days. Infected mice on histological examination exhibited a mild meningitis and this was exacerbated by Berenil therapy and 7 days posttreatment the mice had an acute meningoencephalitis. It would appear that if the infective trypanosomes are completely eliminated from the brain this exacerbated reaction does not occur. It has been found that combined treatment of chronic T. brucei infections with either diminazene aceturate or suramin followed by 5-substituted nitroimidazoles at appropriate dose levels will completely eliminate the infective trypanosomes from the brain and the mice are permanently cured.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6825436

Source DB:  PubMed          Journal:  Contrib Microbiol Immunol        ISSN: 0301-3081


  33 in total

1.  In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors.

Authors:  C J Bacchi; R Brun; S L Croft; K Alicea; Y Bühler
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  The distribution of nifurtimox across the healthy and trypanosome-infected murine blood-brain and blood-cerebrospinal fluid barriers.

Authors:  Sinthujah Jeganathan; Lisa Sanderson; Murat Dogruel; Jean Rodgers; Simon Croft; Sarah A Thomas
Journal:  J Pharmacol Exp Ther       Date:  2010-11-05       Impact factor: 4.030

3.  A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei.

Authors:  P G Kennedy; J Rodgers; F W Jennings; M Murray; S E Leeman; J M Burke
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  African Trypanosome-Induced Blood-Brain Barrier Dysfunction under Shear Stress May Not Require ERK Activation.

Authors:  Brandon J Sumpio; Gautham Chitragari; Takeshi Moriguchi; Sherif Shalaby; Valeria Pappas-Brown; Asif M Khan; Shamala Devi Sekaran; Bauer E Sumpio; Dennis J Grab
Journal:  Int J Angiol       Date:  2014-06-09

5.  In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.

Authors:  Tanja Wenzler; Sihyung Yang; Donald A Patrick; Olivier Braissant; Mohamed A Ismail; Richard R Tidwell; David W Boykin; Michael Zhuo Wang; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

6.  Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-alpha-difluoromethylornithine and standard trypanocides.

Authors:  C J Bacchi; H C Nathan; N Yarlett; B Goldberg; P P McCann; A Sjoerdsma; M Saric; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.

Authors:  Lisa Sanderson; Adil Khan; Sarah Thomas
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  In vitro and in vivo activities of trybizine hydrochloride against various pathogenic trypanosome species.

Authors:  R Kaminsky; R Brun
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.

Authors:  Tanja Wenzler; David W Boykin; Mohamed A Ismail; James Edwin Hall; Richard R Tidwell; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

10.  The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice.

Authors:  F W Jennings; G M Urquhart
Journal:  Z Parasitenkd       Date:  1983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.